Oklahoma health officials on Wednesday will discuss a series of revised rules and regulations to govern the state’s voter-approved medical cannabis access program. The newly proposed changes eliminate several restrictive amendments enacted by the Department earlier this month.
Cannabis law reform groups organize educational forum to highlight the benefits of medical cannabis. A wide-range of experts are expected to provide information and speak on the topic. RSVP today!
Republican Gov. Mary Fallin yesterday signed into law emergency regulations amending SQ 788 — the state’s voter-initiated medical marijuana access law. The Oklahoma State Medical Association, which opposed the passage of SQ 788, lobbied for many of the amendments. Governor Fallin also was a vocal critic of the initiative campaign.
The enactment of medical cannabis access laws is associated with significant reductions in prescription opioid use among Medicaid enrollees, according to just-published data in the journal Addiction. Authors reported, “For Schedule III opioid prescriptions, medical cannabis legalization was associated with a 29.6 percent reduction in number of prescriptions, 29.9 percent reduction in dosage, and 28.8 percent reduction in related Medicaid spending.”
Legislation to significantly expand patients’ access to medical cannabis will become law later this fall following a decision today by Maine lawmakers to override the Governor’s veto.
Everyday NORML Chapters from around the country invest countless hours in advocating for meaningful marijuana law reforms on the local, state and federal level! Here’s a brief rundown of some of their most recent accomplishments. Get involved today!
A majority of Oklahomans today voted to enact State Question 788 — a statewide voter-initiated measure that permits doctors to use their discretion to recommend medical cannabis to those patients who will benefit from it. Oklahoma is now the 31st state to legalize and regulate the use of medical cannabis under state law.
Regulators at the US Food and Drug Administration today granted market approval for Epidiolex, a prescription medicine containing a standardized formulation of plant-derived cannabidiol (CBD), for the explicit treatment of two rare forms of severe epilepsy: Lennox-Gastaut syndrome and Dravet syndrome.
KY NORML is passionate about education. And with the opioid epidemic consuming our state, we feel that it is our duty to share valuable information regarding the relationship between cannabis and opioids.
In just seven days, voters in Oklahoma will have the opportunity to decide in favor of providing much-needed medical marijuana access to patients.